m-h-c
22 articles from this source
- Dermatologists Outperform AI in Skin Cancer Diagnosism-h-c · Jun 11
- Circulating Tumor DNA: Prognostic in Early Breast Cancer, Clinical Utility Pendingm-h-c · Jun 11
- Study: Many Elderly Lung Cancer Patients Miss Systemic Therapym-h-c · Jun 10
- FDA to Review Entyvio Biosimilarm-h-c · Jun 8
- Retatrutide Demonstrates Significant Weight Loss and Glycemic Control in Obesity and Type 2 Diabetesm-h-c · Jun 8
- Pivotal Trial Recruiting for Monthly GLP-1 Weight Loss Treatmentm-h-c · Jun 7
- CONNECT Data Backs CGM Use for Non-Insulin Type 2 Diabetesm-h-c · Jun 6
- App Connects Pain Patients with Cliniciansm-h-c · Jun 6
- Dr. Joanne Mortimer on GLP-1s and Cancer in ASCO 2026m-h-c · Jun 5
- Multiple Myeloma: The Bispecific Era's Future Directionsm-h-c · Jun 1
- Pembrolizumab Benefits Endure in Triple-Negative Breast Cancer at 8 Yearsm-h-c · May 31
- Daraxonrasib: A New Second-Line Pancreatic Cancer Treatmentm-h-c · May 31
- Pediatric Cancer: Molecular Testing Disparities Identified at ASCO 2026m-h-c · May 30
- FDA Approves Afrezza for Pediatric Diabetesm-h-c · May 30
- Lorbrenam-h-c · May 30
- Pediatric Cancer: New Molecular Biomarkers Emerge as Promising Diagnostic Toolsm-h-c · May 29
- Kerendia Receives Priority Review for Type 1 Diabetes and Kidney Diseasem-h-c · May 25
- GLP-1s linked to reduced advanced cancer in patients: ASCO 2026m-h-c · May 25
- Fasting Boosts Ovarian Cancer Chemotherapy Responsem-h-c · May 24
- FDA Approves Langlara, Third Interchangeable Lantus Biosimilarm-h-c · May 24
- Nubeqa Demonstrates Cognitive Advantage Over Xtandi at ASCO 2026m-h-c · May 24
- FDA Approves First Treatment for Chronic Hepatitis Deltam-h-c · May 24